(Q47121100)

English

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer

scientific article published in November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

1 reference

based on heuristic

inferred from title

author name string

Matthew G Fury

1

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Eric Sherman

2

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Donna Lisa

3

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Neeraj Agarwal

4

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Kenneth Algazy

5

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Bruce Brockstein

6

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Corey Langer

7

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Dean Lim

8

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Ranee Mehra

9

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Sandeep K Rajan

10

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Susan Korte

11

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Brynna Lipson

12

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Furhan Yunus

13

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Tawee Tanvetyanon

14

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Stephanie Smith-Marrone

15

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Kenneth Ng

16

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Han Xiao

17

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Sofia Haque

18

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

David G Pfister

19

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

publication date

1 November 2012

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Journal of the National Comprehensive Cancer Network

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

10

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

11

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

1391-1398

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Cetuximab in the treatment of squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Human papillomavirus in HNSCC: recognition of a distinct disease type

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

23 May 2018

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

15 August 2018

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

15 August 2018

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

15 August 2018

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

15 August 2018

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

15 August 2018

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

15 August 2018

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

1 December 2018

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726232

1 December 2018

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23138167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.6004/JNCCN.2012.0144

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5726232

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47121100&oldid=2142267008"